EMNIFY
20.2.2024 15:01:33 CET | Business Wire | Press release
Today, emnify, the leader in cloud-native IoT connectivity solutions, announces the general availability of the industry’s first converged cellular and satellite IoT connectivity on a single emnify IoT eSIM. SuperNetwork SatPlus is offered as part of the emnify SuperNetwork, the leading IoT cellular connectivity service providing multi-network coverage in over 180 countries.
The SuperNetwork SatPlus package combines emnify’s IoT-dedicated cellular access with Skylo’s non-terrestrial network (NTN) satellite service, enabling IoT device manufacturers, OEMs and application and solution providers to add a new level of service enabled by seamless, satellite connectivity failover for devices outside of, or disconnected from, cellular coverage.
SuperNetwork SatPlus opens up a whole new level of IoT connectivity availability for use cases in asset tracking, fleet management, building safety and security, agriculture, and more. IoT businesses can now differentiate their product and service experience and drive their top line revenues by offering a premium level of data connectivity service: ubiquitous coverage even in the most remote areas.
How SuperNetwork SatPlus works
emnify IoT SuperNetwork SatPlus is available in selected European countries and the USA and includes 10MB of cellular connectivity combined with options for 10, 30 or 60 satellite messages per month. With SatPlus, SuperNetwork customers have the security of ubiquitous, uninterrupted IoT connectivity, with seamless switching to satellite networks as devices leave cellular coverage regions. This converged offering is designed for customers that require high availability and a failover solution to be assured that critical application data, such as a high value asset’s position, will always be transmitted.
By enabling both cellular and satellite network access from a single eSIM, single management platform, and single radio module, SatPlus uplevels customer experience and drives down hardware and connectivity costs as it reduces operational overhead associated with adding satellite connectivity.
“Businesses around the world have had to contend with interruptions in their operations and services due to limited terrestrial network infrastructure and rollouts. Bringing together satellite and cellular coverage as a network of networks fills in the blank spaces on the terrestrial coverage map and provides an additional layer of connectivity backup. emnify is excited to be the first to commercially offer this enhanced level of truly global connectivity as part of the expanding emnify IoT SuperNetwork,” said Frank Stoecker, CEO and emnify Co-Founder.
“We are excited to accelerate the availability of the industry’s first converged NTN satellite and cellular connectivity offering through our partnership with emnify,” said Tarun Gupta, CPO and Co-Founder, Skylo. “By delivering satellite and cellular connectivity in a single service, we’re helping IoT businesses increase the reliability and reduce the complexity of IoT connectivity, with a single provider, billing plan, and hardware configuration.”
emnify partners up with leading providers of purpose-built hardware
SatPlus is compatible with market-leading, affordable, converged hardware modules from Murata and IoT chipsets from Sony Semiconductor Israel (Sony), conforming with standard form factors and suitable for a variety of device sizes and designs.
“Designed for cellular IoT applications, the ALT1250 is engineered for devices which prioritize battery life, small size, and global coverage. The 4G/5G LPWA chipset supports 2G, CAT-M, NB-IoT and NB NTN connectivity options and is built to meet the needs of IoT device manufacturers looking to provide new levels of uptime and global coverage across business-critical use cases,” said Dima Feldman, VP Product Management and Marketing at Sony Semiconductor Israel. “Our collaboration with emnify, Murata and Skylo takes our vision forward, enabling IoT devices to connect everywhere.”
Module provider Murata is offering the Type 1SC radio module evaluation board including antenna and application development kit compatible with the SuperNetwork SatPlus service.
“The Type 1SC radio module combined with the Sony ALT1250 chipset and the emnify IoT eSIM provides a compact, low cost, CAT-M & NB-IoT module for a new breed of devices that support both cellular and satellite network protocols to provide global coverage for any type of device,” said Hirokazu Nakae, General Manager, Connectivity Module Product Department at Murata.
Customers interested in getting started with SuperNetwork SatPlus can learn more here. SuperNetwork SatPlus will be generally available in June 2024.
Meet emnify at Mobile World Congress, Barcelona
emnify will be at MWC Barcelona, February 26th to 29th. You can find us at the Berlin Mobile booth in Hall 7 Stand 7B81, or in meeting room 7G70MR. To discuss SuperNetwork SatPlus or any other IoT connectivity requirements, book a meeting: https://www.emnify.com/events/mwc-barcelona
About emnify
emnify is the leading cloud building block for cellular communications in the IoT stack, connecting millions of IoT devices globally – from electric vehicles to energy meters, alarm systems to GPS trackers, thermometers to health wearables. The emnify API and SIM technology connect and secure any kind of IoT deployment to its application back-end. emnify’s cloud-native integrations and no-code workflows ensure seamless lifecycle scalability for deployments of all sizes – from local start-up to global enterprise. The award-winning emnify IoT SuperNetwork is the largest globally distributed mobile cloud core network of its kind, supporting local network access (2G – 5G, LTE-M, NB-IoT and satellite) in over 180 countries from more than 25 cloud regions – and counting. emnify’s solution is built on partnerships with the leading hyperscale cloud service providers, system integrators, and hundreds of network operators worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220129205/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom